Back to top

The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic

Read MoreHide Full Article

For Immediate Release

Chicago, IL – January 06, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Johnson & Johnson (NYSE: (JNJ - Free Report) – Free Report ), Barclays (NYSE: (BCS - Free Report) – Free Report ), Procter & Gamble (NYSE: (PG - Free Report) – Free Report ), Kellogg (NYSE: (K - Free Report) – Free Report ) and Medtronic (NYSE: (MDT - Free Report) – Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Thursday’s Analyst Blog:

Top Research Reports for Friday: JNJ, BCS, PG

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (NYSE: (JNJ - Free Report) – Free Report ), Barclays (NYSE:(BCS - Free Report) – Free Report ), and Procter & Gamble (NYSE: (PG - Free Report) – Free Report ).

Johnson & Johnson shares were up +14.6% last year, widely outperforming the large-cap pharma space (down -3.8%) as well as the S&P 500 index (up +12.1%). While the company is faced with a number of headwinds like unfavorable currency movements, increased competition from generics, pricing pressures and an uncertain global macroeconomic backdrop, the analyst believes that JNJ's diversified business model, deep product pipeline, lack of cyclicality and financial strength position it for continued momentum going forward. We saw this in the company's Q3 earnings report when it beat on the top- and bottom-lines and provided favorable outlook. The analyst expects these trends to continue in the coming periods as well; JNJ is scheduled to report 2016 Q4 results on January 24th. (You can read the full research report on Johnson & Johnson here >> )

Barclays shares have struggled for a while, but the British banking giant appears to have a turned the corner lately, with the stock outperforming the Zacks Foreign Banks industry over the past three months. The analyst thinks that this Zacks Rank #1 (Strong Buy) bank is on track to achieve targeted cost savings this year, driven by continued divestiture of non-core operations world-wide. These are expected to improve operational efficiency and lower expenses, thereby leading to improved profitability over time. Further, Moody’s long term ratings upgrade enhances investors’ confidence in the stock. (You can read the full research report on Barclays here >> )

Procter & Gamble shares were up +8.5% last year, outperforming the Zacks Consumer Staples sector (+4.1%). The analyst likes the company's strong organic sales, which grew 3% in Q3, the best performance in over two years. Productivity improvements and aggressive cost-saving efforts have consistently improved margins with the trend expected to continue going forward. On the flip side, the Zacks analyst points to mature end markets and the negative impact of the strong U.S. dollar as some of the headwinds for the stock. The company is expected to report Q4 results on January 24th, with the current Zacks Consensus EPS of $1.07 on $16.8 billion in revenues. (You can read the full research report on Procter & Gamble here >> )

Other noteworthy reports we are featuring today include Kellogg (NYSE: (K - Free Report) – Free Report ) and Medtronic (NYSE: (MDT - Free Report) – Free Report ).

Free Access: All Zacks Research Reports

Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on JNJ - FREE

Get the full Report on BCS - FREE

Get the full Report on PG - FREE

Get the full Report on K - FREE

Get the full Report on MDT - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.

This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.



More from Zacks Press Releases

You May Like